MannKind Corporation (MNKD)
Market Cap | 1.41B |
Revenue (ttm) | 301.74M |
Net Income (ttm) | 32.80M |
Shares Out | 306.83M |
EPS (ttm) | 0.11 |
PE Ratio | 42.42 |
Forward PE | 58.62 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,209,860 |
Open | 4.500 |
Previous Close | 4.490 |
Day's Range | 4.500 - 4.620 |
52-Week Range | 3.381 - 7.630 |
Beta | 1.02 |
Analysts | Buy |
Price Target | 9.33 (+103.27%) |
Earnings Date | Aug 6, 2025 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipelin... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price target is $9.33, which is an increase of 103.27% from the latest price.
News

MannKind to Present at Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled the...

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted u...

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPha...

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
MannKind Corporation MNKD on Monday agreed to acquire scPharmaceuticals Inc. SCPH for a deal value of up to approximately $360 million, or $5.35 per share.

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript
MannKind Corporation (NASDAQ:MNKD) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript
MannKind Corporation (NASDAQ:MNKD) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.

MannKind Corporation: A Post-Q2 Assessment
Today, we take another look at MannKind Corporation, which specializes in inhaled therapeutics for endocrine and orphan lung diseases, with a market cap of $1.15 billion. The company just reported sec...

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
Strengthens MannKind's capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v.

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

Top 3 Health Care Stocks That May Rocket Higher This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Session

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a on...

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition
MannKind's stock decline is likely due to concerns over Tyvaso DPI competition from Liquidia, but I believe these fears are exaggerated. Tyvaso DPI provides MannKind with a stable revenue base, suppor...

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants Michael Castagna – Chief Executive Officer Chris Prentiss – Chief Financial Officer Con...

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v.

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
Daly to showcase striking “Tired of Pricks?” livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13 Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLA...

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential ...

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Off...

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v.

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MoneyShow's Best Investment Ideas For 2025: Part 8
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur...

MannKind Expands Executive Leadership Team
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled th...